Business Wire

IDC MarketScape Positions TreviPay as a Major Player in Worldwide Accounts Receivable Automation Applications for the Enterprise

4.12.2024 14:00:00 CET | Business Wire | Press release

Share

TreviPay, the most-trusted B2B payments and invoicing network, today announced it has been named a Major Player in the IDC MarketScape: Worldwide Accounts Receivable Automation Applications for the Enterprise 2024 Vendor Assessment1. TreviPay was one of the 14 vendors with a SaaS or cloud offering to be evaluated for their accounts receivable (A/R) strategy and capabilities.

The IDC MarketScape report highlighted a selection of TreviPay’s strengths including:

  • Robust APIs: “The TreviPay suite of APIs enables merchants to directly integrate invoicing into any ecommerce platform, point-of-sale environment, or order management platform. In addition, TreviPay enables a white-labeled solution that may be embedded within the checkout, giving buyers a line of sight into how much credit they have available in real time. Terms to buyer and settlement with client are both independently configurable, enabling guaranteed DSO.”
  • Expanding/Expansive Ecosystem: “The most recent investments include a strategic partnership with Mastercard to give suppliers the ability to extend trade credit financing and invoicing using Mastercard's commercial card payment capabilities. Also, TreviPay recently announced a strategic partnership with Allianz Trade that integrates Allianz Trade's credit insurance into TreviPay solution for enhanced risk management that enables funding capabilities.”

The evaluation assesses vendors in two primary categories: strategies and capabilities. The strategy criteria measure how well the vendor’s future strategy aligns with what customers will require over the next three to five years, and measures functionality roadmap, extensibility, scalability, customer experience and 3rd platform strategy. And the capabilities criteria assess agility, automation, extensibility, flexibility, functionality, portfolio benefits, 3rd platform usage, and visibility.

“Traditional accounts receivable processes are ripe for disruption. As we saw in our vendor assessment, this is dynamic market with a range of A/R solutions for the enterprise, but only a few, like TreviPay, that offer an integrated order-to-cash solution along with native financing options,” said Kevin Permenter, senior research director, Financial Applications at IDC.

This recognition follows TreviPay’s recent news to expand its automated order-to-cash offering and further enhance the buyer onboarding experience by reducing manual reviews and speeding up credit decisioning to near real-time. It also comes on the heels of the TreviPay Crossroads conference which brought together clients, partners and industry leaders from across the B2B payments ecosystem.

“We are thrilled to be recognized by IDC MarketScape as a Major Player in Accounts Receivable Automation Applications for the Enterprise report noting our deep payment management functionality, robust APIs and expansive ecosystem as key strengths,” said Brandon Spear, CEO of TreviPay. “As a first-time participant in this evaluation, it is particularly gratifying to see our distinctive capabilities and forward-looking strategies recognized in this assessment. With our focus on working with the largest global brands, we have seen the massive opportunity in automating core A/R processes, offering more payment choice to buyers and providing perfect DSO to financial teams.”

Download an excerpt of the vendor assessment.

1 IDC, IDC MarketScape: Worldwide Accounts Receivable Automation Applications for the Enterprise 2024 Vendor Assessment, #US51740924, December 2024

About TreviPay

At TreviPay, we believe loyalty begins at the payment. By understanding the diverse and unique requirements of B2B sellers, TreviPay’s global B2B payments and invoicing network enables enterprises to provide payments choice and convenience, open new markets and automate accounts receivables. With more than four decades of experience, TreviPay serves leaders looking to build loyalty while driving efficiency and embracing new digital channels, especially in industries with large distribution networks such as manufacturing, retail, and transportation. For more information, visit www.trevipay.com.

About IDC MarketScape

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204578799/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye